Cargando…

A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE‐IT Study

BACKGROUND: MAT9001 is an omega‐3 free fatty acid (FFA) formulation containing mainly eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA). Compared with icosapent ethyl (EPA‐ethyl esters [EE]), EPA+DPA‐FFA previously showed enhanced triglyceride lowering and higher plasma EPA when both were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maki, Kevin C., Bays, Harold E., Ballantyne, Christie M., Underberg, James A., Kastelein, John J. P., Johnson, Judith B., Ferguson, James J., Bays, Harold, Blomer, Allison, Kelley, Kathleen, Patel, Alpa, Scott, John K, Surowitz, Ronald Z, Toth, Philip D, Trivedi, Rupal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075326/ https://www.ncbi.nlm.nih.gov/pubmed/35232215 http://dx.doi.org/10.1161/JAHA.121.024176

Ejemplares similares

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
por: Bays, Harold E., et al.
Publicado: (2013)

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
por: Ballantyne, Christie M., et al.
Publicado: (2019)

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
por: Brinton, Eliot A, et al.
Publicado: (2013)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
por: Khan, Muhammad Shoaib, et al.
Publicado: (2021)

Correction to: Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022)

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
por: Ballantyne, Christie M., et al.
Publicado: (2022)

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
por: Bhatt, Deepak L., et al.
Publicado: (2023)

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
por: Backes, James, et al.
Publicado: (2016)

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
por: Bays, Harold E., et al.
Publicado: (2021)

Adiposopathy, “Sick Fat,” Ockham’s Razor, and Resolution of the Obesity Paradox
por: Bays, Harold
Publicado: (2014)

Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction
por: Bays, Harold
Publicado: (2014)

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
por: Bays, Harold
Publicado: (2013)

Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
por: Bays, Harold E
Publicado: (2012)

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
por: Bays, Harold E
Publicado: (2014)

Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)
por: Bays, Harold Edward
Publicado: (2020)

Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review
por: Bays, Harold Edward
Publicado: (2023)

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl
por: Hassan, Amir, et al.
Publicado: (2014)

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT
por: Selvaraj, Senthil, et al.
Publicado: (2022)

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022)

Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors
por: Bays, Harold, et al.
Publicado: (2007)

Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Lazarus, Ethan, et al.
Publicado: (2022)

Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Tondt, Justin, et al.
Publicado: (2022)

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021)

Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3
por: Pirillo, Angela, et al.
Publicado: (2015)

Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Fitch, Angela K., et al.
Publicado: (2022)

Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters
por: Dayspring, Thomas D
Publicado: (2011)

Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia
por: Han, Eugene, et al.
Publicado: (2016)

Treatment of Severe Hypertriglyceridemia During Pregnancy With High Doses of Omega-3 Fatty Acid and Plasmapheresis
por: Nguyen, Nguyen T., et al.
Publicado: (2021)

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin
por: Braeckman, Rene A., et al.
Publicado: (2014)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
por: Peterson, Benjamin E., et al.
Publicado: (2020)

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
por: Kastelein, John J.P., et al.
Publicado: (2017)

Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Bays, Harold Edward, et al.
Publicado: (2022)

ODP155 Successful Treatment of PEG-Asparaginase Related Hypertriglyceridemia with Omega-3 Acid Ethyl Esters
por: Radovanovic, Natasa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r5refk810i26n39u2t09jh8db2